Glofitamab monotherapy induces high complete response rates and manageable safety in Chinese patients with heavily pretreated relapsed or refractory diffuse large B-cell lymphoma

• Yu-Qin Song,
• Hui-Lai Zhang,
• Hui-Qiang Huang,
• Qing-Yuan Zhang,
• Hong-Mei Jing,
• Chao Wang,
• Chun Wu,
• Dong-Hang Li,
• Yu Dai,
• Kathryn Humphrey,
• Jun Zhu

Affiliations

Yu-Qin Song

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing

Hui-Lai Zhang

Tianjin Medical University Cancer Institute and Hospital, Tianjin

Hui-Qiang Huang

Sun Yatsen University Cancer Center, Guangzhou

Qing-Yuan Zhang

Harbin Medical University Cancer Hospital, Harbin

Hong-Mei Jing

Peking University Third Hospital, Beijing

Chao Wang

Roche (China) Holding Ltd., Shanghai

Chun Wu

Roche (China) Holding Ltd., Shanghai

Dong-Hang Li

Roche (China) Holding Ltd., Shanghai

Yu Dai

Roche RD Center (China) Ltd., Shanghai

Kathryn Humphrey

Roche Products Ltd., Welwyn Garden City, UK

Jun Zhu

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing